Bayer HealthCare is introducing its Jetstream Atherectomy System for the treatment of peripheral arterial disease in the lower limbs at CIRSE (15–19 September, Lisbon, Portugal).
The device can be used to treat a wide range of vessel diameters, from the superficial femoral artery to below the knee, and features continuous active aspiration. This technology allows its use in thrombus, soft plaque and calcified lesions.
“Jetstream is a highly effective technology for the treatment of chronic occlusive and thrombotic peripheral arterial disease,” said Thomas Zeller, Department of Angiology, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany, and co-principal investigator of the pivotal European multicentre clinical trial for the Jetstream technology. “In the pivotal study of 172 patients, many of whom had more than one lesion, we successfully restored flow through 99% of the lesions and demonstrated significant clinical improvement post-procedure at 30 days, six and 12 months on both Rutherford and ABI scores.”
“The device allows us to quickly restore blood flow to the limbs by removing calcifications in diffusely diseased segments–including traditional zones where stents cannot be used–without the higher risks inherent in surgery,” said Anderson Mehrle, Jane Phillips Medical Center, Bartlesville, USA.
